alitretinoin

Phase 3Completed

0 views this week 0 watching💤 Quiet

Interest: 34/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Eczema

Conditions

Eczema

Trial Timeline

May 1, 2007 → —

NCT ID

NCT00519675

About alitretinoin

alitretinoin is a phase 3 stage product being developed by Basilea Pharmaceutica for Eczema. The current trial status is completed. This product is registered under clinical trial identifier NCT00519675. Target conditions include Eczema.

What happened to similar drugs?

2 of 12 similar drugs in Eczema were approved

Approved (2) Terminated (2) Active (8)

✅Pimecrolimus cream 1%NovartisApproved

✅DupilumabRegeneron PharmaceuticalsApproved

🔄Colloidal Oatmeal CreamJohnson & JohnsonPhase 3

🔄AbrocitinibPfizerPhase 3

🔄alitretinoin + PlaceboGSK plcPhase 3

❌Ruxolitinib cream + VehicleIncytePhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (5)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01407679	Phase 2	Terminated	Aug 1, 2011	Apr 1, 2014	Lupus Erythematosus, Cutaneous
NCT00519675	Phase 3	Completed	May 1, 2007	—	Eczema
NCT00309621	Phase 3	Completed	Apr 1, 2006	May 1, 2007	Hand Dermatoses
NCT00124436	Phase 3	Completed	Mar 1, 2005	Feb 1, 2007	Hand Dermatoses
NCT00124475	Phase 3	Completed	Dec 1, 2004	Sep 1, 2007	Hand Dermatoses

Competing Products

20 competing products in Eczema

See all competitors

Product	Company	Stage	Hype Score
1% Colloidal Oatmeal Balm	Johnson & Johnson	Pre-clinical	18
Colloidal Oatmeal Cream	Johnson & Johnson	Phase 3	40
Pimecrolimus cream 1%	Novartis	Approved	43
Abrocitinib	Pfizer	Phase 3	47
Dupilumab + Placebo	Sanofi	Phase 2	31
Amlitelimab + Placebo	Sanofi	Phase 2	35
alitretinoin + Placebo	GSK plc	Phase 3	40
Dupilumab	Regeneron Pharmaceuticals	Approved	39
Adventan® (methylprednisolone aceponate 0,1%)	Bayer	Phase 1	26
Ruxolitinib cream + Vehicle	Incyte	Phase 3	29
Ruxolitinib cream + Vehicle	Incyte	Phase 2	32
Ruxolitinib cream + Vehicle	Incyte	Phase 3	29
ARQ-151 Cream 0.15% or ARQ-151 Cream 0.05%	Arcutis Biotherapeutics	Phase 3	34
Roflumilast Cream + Vehicle cream	Arcutis Biotherapeutics	Phase 3	34
ARQ-151 cream 0.05%	Arcutis Biotherapeutics	Phase 2	29
Roflumilast Cream 0.05% + Vehicle Cream	Arcutis Biotherapeutics	Phase 3	34
Roflumilast Cream 0.15% + Vehicle Cream	Arcutis Biotherapeutics	Phase 3	34
ARQ-151 cream 0.15% + ARQ-151 cream 0.05%	Arcutis Biotherapeutics	Phase 1	23
ARQ-252 cream 0.3% + ARQ-252 cream 0.1% + ARQ-252 Vehicle Cream	Arcutis Biotherapeutics	Phase 1/2	26
LAS41003 + LAS189962 + LAS189961	Almirall	Phase 2	29